1,831 件 ・ 関連度順
概要と使いどころ
Use when adding hypermedia links to REST responses, building self-describing APIs, or implementing Spring HATEOAS. Use when you see EntityModel, CollectionModel, or RepresentationModel in the project.
日本語の概要は準備中です。原文の説明を表示しています。
Use when the project follows hexagonal (ports & adapters) architecture. Prevents domain code from depending on Spring or JPA. Use when you see packages like domain/, application/, infrastructure/, or adapters/ in the project structure.
日本語の概要は準備中です。原文の説明を表示しています。
Audita calidad de código Kotlin/Spring Boot en este proyecto. Úsalo cuando el usuario pida revisar código, verificar estándares, hacer un code review, auditar calidad, ejecutar linters, verificar cobertura, o antes de hacer commit/PR. También úsalo cuando mencionen KTLint, Detekt, JaCoCo, cobertura, o simplemente digan "revisa el código" / "está listo para commit" / "qué tan bueno está el código".
日本語の概要は準備中です。原文の説明を表示しています。
Use when building MCP (Model Context Protocol) servers in Java/Spring Boot. Covers tool registration, resource exposure, prompt templates, and production deployment using the official MCP Java SDK. Use when user mentions MCP, AI agent integration, or tool calling.
日本語の概要は準備中です。原文の説明を表示しています。
Use when configuring Spring Boot as an OAuth2 resource server, validating JWTs from an external auth provider (Keycloak, Auth0, Okta, Cognito), extracting claims, or implementing scope-based authorization.
日本語の概要は準備中です。原文の説明を表示しています。
Use when implementing error handling, exception mappers, or error response formatting. Enforces RFC 9457 (Problem Details for HTTP APIs) using Spring's built-in ProblemDetail.
日本語の概要は準備中です。原文の説明を表示しています。
Provides expert knowledge for implementing and reviewing application security following OWASP Top 10 (2021), with stack-specific patterns for Spring Boot, Django, Next.js, and Astro.
日本語の概要は準備中です。原文の説明を表示しています。
Use when adding monitoring, metrics, logging, or tracing to Spring AI or LLM integration code. Covers token tracking, latency measurement, cost estimation, and prompt/response logging. Use when user mentions AI monitoring, token costs, or LLM observability.
日本語の概要は準備中です。原文の説明を表示しています。
Use when implementing caching, session storage, rate limiting, or any Redis integration. Covers cache-aside pattern, key naming, TTL strategy, and serialization config.
日本語の概要は準備中です。原文の説明を表示しています。
Use when generating or modifying any Spring Boot class — controllers, services, repositories, DTOs, mappers, or configuration. Enforces strict layer separation and prevents business logic from leaking across boundaries.
日本語の概要は準備中です。原文の説明を表示しています。
Use when generating JPA entities, repositories, queries, or anything touching the persistence layer. Covers entity conventions, N+1 prevention, projections, and query patterns.
日本語の概要は準備中です。原文の説明を表示しています。
Use formula-backed WorkPaper JSON and MCP tools for agent spreadsheet tasks without driving Excel or a browser UI.
日本語の概要は準備中です。原文の説明を表示しています。
Write and debug spreadsheet formulas (Excel/Google Sheets), pivot tables, and array formulas; translate between dialects; use when users need working formulas with examples and edge-case checks.
日本語の概要は準備中です。原文の説明を表示しています。
Designs donor/repair templates for precise CRISPR knock-ins -- choosing the format (ssODN, long-ssDNA/Easi-CRISPR, dsDNA/plasmid, AAV6), sizing homology arms, placing the cut within ~10 bp of the edit, and adding a mandatory codon-checked blocking (PAM/seed) mutation so the edited allele is not re-cut. Frames the HDR-vs-NHEJ-vs-MMEJ pathway competition, the MMEJ (PITCh) and homology-independent (HITI/HMEJ) alternatives for post-mitotic cells, ssODN strand/asymmetry choice, phosphorothioate end-protection, and ranked HDR enhancers. Use when designing a donor for a point mutation, epitope/fluorophore tag, allele replacement, or knock-in, or when HDR efficiency is low. Guide design and base/prime editing are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Designs cytosine (CBE, C-to-T) and adenine (ABE, A-to-G) base-editor guides by positioning the target base at the activity-peak of the editing window (protospacer positions ~5-7, PAM-distal numbering), minimizing bystander edits for product purity, reading dinucleotide context (APOBEC1 TC favored / GC disfavored), and selecting the editor variant (BE4max, ABEmax, ABE8e, YE1/SECURE, TadCBE, CGBE, SpG/SpRY-BE). Covers knockout by premature stop (CRISPR-STOP/iSTOP) and splice-site disruption, the three off-target classes (Cas-dependent, Cas-independent DNA, RNA), outcome prediction (BE-Hive/DeepBE), and the base-vs-prime-vs-HDR decision. Use when installing a transition mutation without a double-strand break, knocking out a gene without indels, or choosing CBE vs ABE. Generic guide scoring, prime editing, and HDR donors are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes base-editing screens for variant function. Covers library design (Sanson 2020 GRACE, Hanna 2021 BRCA1/2 SNV scanning, Cuella-Martin 2021), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end, wider for ABE8e), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.
日本語の概要は準備中です。原文の説明を表示しています。
Batch effect correction for CRISPR screens covering ComBat empirical-Bayes, RUV, SVA, control-sgRNA normalization, and the model-based alternative of including batch as a covariate in MAGeCK MLE or Chronos. Covers screen-specific batch sources (passage cohort, library lot, infection day, sequencing run, Cas9 lot, FBS lot), PCA + variance-decomposition diagnostic to decide if correction is needed, when correction harms biology by over-correcting condition into batch, limma removeBatchEffect for visualization-only correction, and relationship to multi-condition design matrices. Use when combining screens for joint analysis, when passage cohort confounds biology, when DepMap-style panels need Chronos with batch covariates, when picking ComBat vs RUV, or when correction harms biology and should be replaced with explicit covariate modeling.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 (Mathis 2023/2024) for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2 / PE3 / PE3b / PEmax / PEAR variants, MOSAIC in situ saturation mutagenesis (Hsu JY et al 2024 bioRxiv), the PRIME pooled-screen methodology (Erwood/Doman 2023 Nat Biotechnol 41:885; ~3,699 ClinVar variant screens), chromatin context as a primary determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.
日本語の概要は準備中です。原文の説明を表示しています。
Identifies essential genes from CRISPR-Cas9 fitness screens using BAGEL2 (Kim & Hart 2021 Genome Med), a Bayesian classifier scoring per-gene Bayes Factors via log-likelihood ratios over per-sgRNA fold changes, calibrated against CEGv2 core-essentials (Hart 2017 G3, ~684 genes) and NEGv1 non-essentials (Hart 2014, ~927 genes). Covers the fc + bf + pr workflow, the linear-extrapolation improvement over BAGEL1 truncation, multi-target off-target correction, tumor-suppressor sensitivity (BAGEL2 detects enrichment), and BF-to-FDR calibration (BF >6 ≈ FDR 0.05 from Hart 2017). Use when classifying essential vs non-essential genes, calibrating BAGEL2 thresholds against PR curves, identifying tumor suppressors alongside essentials, comparing BAGEL2 hits to MAGeCK / drugZ, or generating publication-quality essentiality calls.
日本語の概要は準備中です。原文の説明を表示しています。
Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.
日本語の概要は準備中です。原文の説明を表示しています。
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
日本語の概要は準備中です。原文の説明を表示しています。
Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.
日本語の概要は準備中です。原文の説明を表示しています。
Design performant animation systems with Framer Motion, GSAP, View Transitions API, and spring physics. Activate on: page transitions, micro-interactions, scroll animations, layout animations, spring physics. NOT for: CSS-only hover effects (use css-in-js-architect), video/canvas rendering (use creative-coding-expert).
日本語の概要は準備中です。原文の説明を表示しています。
repositoryを調査し、`docs/PLAN/YYMMDD_{slug}.md` にPhase、Gate、完了状態、実行ルール、チェック項目を持つ自己完結した永続計画を作成または再構成する。Use when the user asks for simple-plan、チェックリスト式の計画、複数停止点を持つ中規模作業、段階的なapp分割やlocal migration、production前Gate、または既存planの構成変更。単発Sprintでは収まらないが、詳細なworker委任計画までは不要な作業向け。既存planをそのまま実行・再開するだけの場合は使わない。